Navigation Links
YM BioSciences third quarter 2010 operational and financial results
Date:5/13/2010

ch (AACR) Annual Meeting held on April 17-21 in Washington, DC. - Presented posters on CYT387 and CYT997, the Company's novel vascular disrupting agent, at the Lorne Cancer Conference in Lorne, Victoria, Australia. - Published pivotal preclinical data for CYT387 as a First Edition in the premier hematology journal Blood. - Had granted two additional patents in the US for AeroLEF(R), our proprietary, inhaled-delivery composition of free and liposome- encapsulated fentanyl for the treatment of moderate to severe acute pain. - Reported positive results on the selective activity of a highly potent antibody-radionuclide with nimotuzumab in breast cancer cells resulting from a collaboration with researchers at the University of Toronto. - Appointed Rogerio C. Lilenbaum, M.D., M. Sc., Minesh Mehta, M.D., and Roman Perez-Soler, M.D., together with two additional leading US oncologists have to a US Consultative Committee to YM on the ongoing development YM's anti-cancer products. - Closed registered direct offering for gross proceeds of approximately US $17.5 million.

Subsequent to the quarter end, the Company initiated an "At-The-Market" financing facility for up to 7.5 million common shares.

"The substantial liquidity in our share trading permits us to access this innovative financing mechanism which will provide us with important flexibility in the timing of any future financing and, if implemented, should significantly reduce our overall cost of capital," said Mr. Allan. "This established mechanism has been used across multiple industries by numerous companies including several life-sciences companies and is designed to result in the issuance of shares at no discount to the quoted market at the time of a transaction. We are not required to sell any shar
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
3. YM BioSciences announces controlled equity offering
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
5. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. YM BioSciences closes US$17.5 million financing
10. YM BioSciences to raise approximately US$15 million
11. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014  Roche (SIX: RO, ROG; OTCQX: ... Inc. (Bina), a privately held company based in ... Bina provides a big data platform for centralized ... data. Bina,s proprietary on-market Genomic Management Solution, Bina-GMS ... to perform fast and scalable analyses to maximize ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 ... nation’s leading specialty pharmacies, has an expanded team ... clinical pharmacy consultants for prescriber offices in their ... , “We have a variety of Regional ... example, those specializing in hepatitis C help prescribers ...
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
Breaking Biology Technology:Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... System Offers Healthcare Workers Consistent Cleaning , ... , IRVINE, Calif., Dec. 16 ... the availability of the EVOTECH(TM) Endoscope Cleaner and ... labor-intensive manual cleaning of endoscopes. The results of ...
... to review Intermezzo(R) (zolpidem tartrate sublingual lozenge) as the ... middle-of-the-night awakenings , , ... a privately-held specialty pharmaceutical company, announced today that it ... Administration (FDA) that the New Drug Application (NDA) for ...
... Dec. 16 Anesiva,Inc. (Nasdaq: ANSV ... Phase 3,trial evaluating Adlea(TM), its long-acting, non-opioid analgesic ... post-surgical,pain versus placebo (p=0.03) following total knee arthroplasty ... 48 hours after surgery. The trial also,met its ...
Cached Biology Technology:ASP Announces Availability of EVOTECH(TM) Endoscope Cleaner and Reprocessor - First Commercially Available System to Eliminate Manual Cleaning of Endoscopes 2Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 2Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 3Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 4Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 5Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 3Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 4
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ... the condition and the best ways to treat it. ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... way to scan brain tumors and predict which ones will ... ever starts treatment. By linking high water movement in ... 70 percent accuracy which patients, tumors were the least likely ... considers himself lucky. When his aggressive brain cancer returned ...
... parts of living organisms come packaged with ribbons. The ... into three-dimensional structures to work properly. But when for ... happen, and in humans misfolded-protein disorders include Alzheimer,s and ... three decades tried to understand what makes proteins fold ...
... trees have declined in Yosemite National Park during the ... role. The number of large-diameter trees in the ... U.S. Geological Survey and University of Washington scientists compared ... to the most recent records from 1988�. A ...
Cached Biology News:A crystal ball for brain cancer? 2A crystal ball for brain cancer? 3New computer simulation helps explain folding in important cellular protein 2New computer simulation helps explain folding in important cellular protein 3
... Clean and Accurate Results Laser Capture ... the sensitivity and accuracy of molecular assays ... types and multi-cellular structures isolated from whole ... to microdissection-developed in 1996 at the National ...
... antibody raised against a partial ... Immunogen: ZFHX4 (NP_078997, 2 ... recombinant protein with GST tag. ... NM_024721 ...
... specificity and signaling of the members of ... modified by alternative splicing--which has important implications ... can perform a classical expression profiling and ... alternatively spliced forms of the gene that ...
... Alternative Splicing plays an important role in ... apoptosis and cell death. Splice variants have ... and inhibition of defined apoptotic pathways. With ... can perform a classical expression profiling and ...
Biology Products: